This past summer, our latest publication in the FinWeight series sparked a nationwide conversation and made headlines across Finland. But what is the study really about, and why is it meaningful not only nationally but also globally?
Back in 2018, MedEngine joined forces with experts at the Finnish Institute for Health and Welfare (THL) and its Biobank, Helsinki University Hospital (HUS), and the pharmaceutical company Novo Nordisk to launch the FinWeight study—the most comprehensive investigation to date into the impact of obesity in Finland. The goal was to generate solid evidence on a disease that is too often misunderstood, stigmatized, or dismissed as a matter of lifestyle choice.
“Obesity is a chronic disease shaped by genetic, environmental, biological, behavioral, and social factors. It isn’t a lack of willpower or simply the illnesses it causes. The body defends excess fat through complex brain circuits that regulate satiety, creating a cycle that undermines health,” says Professor Kirsi Pietiläinen, a leading obesity researcher at the University of Helsinki.
FinWeight’s strength lay in its data. Built on the FinHealth 2017 survey, the study stood out by providing detailed clinical information, such as standardized measurements of height and weight, that are rarely available in health registers. By linking this rich dataset with Finland’s comprehensive health and social care registers, we were able to examine the associations between body mass index (BMI) and a wide range of health and patient-reported outcomes. The analysis also extended to healthcare resource utilization, lost productivity, and the overall economic burden of obesity, offering an exceptionally detailed view of its multifaceted impact.
The results from a nationally representative sample of more than 5,500 Finnish adults revealed that obesity was associated with reduced quality of life, impaired work ability, and widespread metabolic illness—more than 90 percent of individuals with obesity were metabolically unhealthy. The societal price tag was staggering: at least €2.54 billion annually, with more than half stemming from lost productivity and the rest from direct healthcare expenditures.
For Tero Saukkonen, Medical Director at Novo Nordisk, FinWeight addressed a glaring knowledge gap. “When the study began, Finland lacked up-to-date evidence on the burden of obesity on the healthcare system and society overall. FinWeight filled that gap and, just as importantly, sparked debate. The quality of the registers used makes this research globally interesting, not just nationally important.”
These numbers, Pietiläinen stresses, should be interpreted with care. “They are not intended to blame individuals. The real problem is systemic—insufficient prevention and lack of access to effective interventions. Untreated obesity costs far more than treated obesity.” She emphasizes that the findings should serve as a collective wake-up call, urging stakeholders to come together to plan and commit to a unified national strategy to address this pressing challenge.
“Numbers serve as valuable tools for initiating discussions, especially when we want to highlight challenges in current care practices. They have been instrumental in facilitating dialogue among clinicians, policymakers, and the public,” summarizes Tero Saukkonen.
The study’s modular design, carried out in phases between 2019 and 2025, enabled the continuous generation of evidence and publication of new results along the way. This approach ensured that insights could be shared and acted upon as soon as they emerged, turning research into an ongoing dialogue rather than a single endpoint.
For MedEngine and its partners, FinWeight exemplifies how collaborative, data-driven research can illuminate blind spots in healthcare and pave the way for a paradigm shift. In today’s rapidly evolving therapeutic landscape, access to up-to-date information on the impact of obesity is more crucial than ever—especially as new treatment options become available.
The challenge now is to turn evidence into action. As Pietiläinen concludes: “We know what to do. The question is whether there is the will to do it.”
Publications:
1. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22978-9
2. https://www.tandfonline.com/doi/full/10.1080/20016689.2023.2166313
3. https://link.springer.com/article/10.1007/s10198-022-01507-0
4. https://link.springer.com/article/10.1007/s11136-021-02993-0
5. https://www.terveysportti.fi/apps/dtk/tyt/article/ttl01947?toc=1108366
6. https://www.laakarilehti.fi/tieteessa/alkuperaistutkimukset/lihavuuden-yhteys-elamanlaatuun-ja-tyokykyyn-suomalaisessa-aikuisvaestossa/
